Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on KRAS-mutated human colon cancer cell lines with different microsatellite instability
- Authors
- Kim, Kyung-Ok; Park, Woo-Jae; Jung, YunJae; Lee, Won-Suk
- Issue Date
- Nov-2020
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Colorectal cancer; KRAS-mutation; microsatellite instability; MEK kinase inhibitor; BRAF kinase inhibitor; chemotherapy
- Citation
- JOURNAL OF CHEMOTHERAPY, v.32, no.8, pp 437 - 444
- Pages
- 8
- Journal Title
- JOURNAL OF CHEMOTHERAPY
- Volume
- 32
- Number
- 8
- Start Page
- 437
- End Page
- 444
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69615
- DOI
- 10.1080/1120009X.2020.1829326
- ISSN
- 1120-009X
1973-9478
- Abstract
- We analyzed responsiveness of KRAS-mutated CRC cell lines with distinctive MSI status against mitogen-activated protein kinase (MEK) inhibitor (selumetinib; AZD) and/or B-raf proto-oncogene (BRAF) kinase inhibitor (vemurafenib; PLX). The viability of MSI-high (MSI-H) KRAS-mutated LS174T cells treated with AZD or PLX was 24.5 +/- 0.9% or 71.4 +/- 3.6%, respectively, and the viability of microsatellite stable (MSS) KRAS-mutated SW480 cells for AZD or PLX was 57.4 +/- 3.1% or 43.1 +/- 1.8%, respectively. These observations imply that the therapeutic efficacy of MEK kinase inhibitors or BRAF kinase inhibitors against KRAS-mutated colon cancer cells may differ between MSI-H and MSS. However, a combination of both inhibitors synergistically inhibits the proliferation of KRAS-mutated colon cancer cells regardless of MSI status. The underlying synergistic cytotoxic efficacy of AZD/PLX combination on KRAS-mutated colon cancer cells with different MSI status was further substantiated by markedly decreased phosphorylation of ERK in both LS74T and SW480 cell lines upon AZD and PLX treatment. Based on these collective data, we propose that MSI status should be considered when MEK kinase inhibitor or BRAF kinase inhibitor is treated for KRAS-mutated colon cancer, and that combination of both inhibitors synergistically inhibit proliferation of KRAS-mutated colon cancer cells independent of MSI status.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/69615)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.